Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Head-to-head trials have shown Compounded Tirzepatide produces greater early weight reduction than semaglutide-based medications in direct comparisons
The glucagon-like peptide (GLP-1) receptor agonist injections regulates blood sugar levels and becomes known for its weight loss side effects
Third, FDA could not always define the molecule itself
In China - which represents the region's largest potential market - domestic competitors are developing biosimilar tirzepatide formulations that could undercut Zepbound's pricing
Some patients in edge cases may still be reviewed individually
Between 2022 and 2026, GLP-1 use among people aged 1325 seeking obesity treatment increased from 88.2% to 96.1% and outpaced metabolic and bariatric surgery (MBS) use, which saw a decline from 11.6% to 3.7%
